NMNikos Maniadakis

Nikos Maniadakis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nikos Maniadakis has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 6 August 2013
      • Vol. 54  (4) , 289-300

    Economic evaluation of dabigatran etexilate in the management of atrial fibrillation in Greece.

    by George K Andrikopoulos, Vasilis Fragoulakis, Nikos Maniadakis

    The objective of the present study was to evaluate, from an economic perspective, dabigatran etexilate in comparison to existing pharmaceutical therapeutic options available for the protection of moderate-to-high risk patients with non-valvular atrial fibrillation from cardioembolic risk. An existing Markov model was adapted to the Greek setting to reflect the natural course of the disease and the management of patients with different therapies. The model predicts health and economic outcomes and the implications for the social security system during the course of a patient's lifetime. The data for the population of the model were derived from the international literature and local economic databases. The incremental cost per quality-adjusted life year (QALY) of dabigatran 150 mg twice daily relative to the other therapies varied from €5547 to €11,762 and that of dabigatran 110 mg twice daily from €7398 to €16,437. The incremental cost per QALY of dabigatran 150 mg relative to aspirin, the least costly option, was €11,762 and relative to warfarin and acenocoumarol, the local standards of care, it was €11,400 and €11,224 respectively, well below the local thresholds of acceptance. Dabigatran etexilate may represent a cost-effective option for the prevention of thromboembolic events in AF patients at moderate-to-high risk of stroke or systemic embolism.


  • Open Access

    Factors influencing prescribing behaviour of physicians in Greece and Cyprus: results from a questionnaire based survey

    by Mamas Theodorou, Vasiliki Tsiantou, Andreas Pavlakis, Nikos Maniadakis, Vasilis Fragoulakis, Elpida Pavi, John Kyriopoulos

    Background: Over the past few decades, drug and overall healthcare expenditure have risen rapidly in most countries. The present study investigates the attitudes and the factors which influence physician prescribing decisions and practice in Greece and Cyprus. Methods: A postal questionnaire was developed by researchers at the Department of Health Economics at the National School of Public Health in Greece, specifically for the purposes of the study. This was then administered to a sample of 1,463 physicians in Greece and 240 physicians in Cyprus, stratified by sex, specialty and geographic region. Results: The response rate was 82.3% in Greece and 80.4% in Cyprus. There were similarities but also many differences between the countries. Clinical effectiveness is the most important factor considered in drug prescription choice in both countries. Greek physicians were significantly more likely to take additional criteria under consideration, such as the drug form and recommended daily dose and the individual patient preferences. The list of main sources of information for physicians includes: peer-reviewed medical journals, medical textbooks, proceedings of conferences and pharmaceutical sales representatives. Only half of prescribers considered the cost carried by their patients. The majority of doctors in both countries agreed that the effectiveness, safety and efficacy of generic drugs may not be excellent but it is acceptable. However, only Cypriot physicians actually prescribe them. Physicians believe that new drugs are not always better and their higher prices are not necessarily justified. Finally, doctors get information regarding adverse drug reactions primarily from the National Organisation for Medicines. However, it is notable that the majority of them do not inform the authorities on such reactions. Conclusion: The present study highlights the attitudes and the factors influencing physician behaviour in the two countries and may be used for developing policies to improve their choices and hence to increase clinical and economic effectiveness and efficiency.


    • 31 March 2009
      • Vol. 50  (2) , 105-18

    Analysis of published economic evaluations of angiotensin receptor blockers.

    by Dorina Theodoratou, Nikos Maniadakis, Vasilis Fragoulakis, Eugenia Stamouli

    In this study we reviewed the published literature on the economic evaluation of the use of angiotensin receptor blockers (ARBs) for the treatment of hypertension, either primary or due to diabetes. An extensive literature review was undertaken. The HEED (Health Economic Evaluations Database) of the Office for Health Economics and the NHS-EED (NHS Economic Evaluation Database) databases were searched. Keywords used were "losartan", "irbesartan", "valsartan", "candesartan", "olmesartan", "telmisartan", "eprosartan", "primary hypertension" and "diabetes". The study included all articles retrieved from 2001 onwards. Exclusion criteria included economic evaluations of ARBs for other indications (e.g. heart failure, myocardial infarction, etc.), an underage population, as well as prevalence studies of hypertension for a disease-specific population. Of the 63 studies retrieved in the literature search, 35 were included in the review. The majority of the studies were of irbesartan (16) or losartan (8). In each study, the model used country-specific data to project and evaluate the clinical and cost outcomes of the treatment arms. The most common method undertaken was cost-consequence analysis (52.94%) followed by cost-effectiveness analysis (32.35%). In most cases, costs and benefits results were not synthesised. Results failed to show a clear advantage in favour of specific therapy, as the outcomes suffered from heterogeneity, referred to specific circumstances and were rather difficult to compare. For different treatment comparators, all the analyses demonstrated an improved life expectancy and a cost-saving choice. The robustness of results was tested with a series of sensitivity analyses, which showed a statistically significant result in each case. The evidence from this review suggests that the available ARBs represent a cost-saving and cost-effective treatment compared with other conventional treatment options for patients with hypertension and associated conditions. However, there are no meaningful differences between available ARBs, as the design of clinical and economic studies makes it difficult to find any such differences.


  • XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis

    by Nikos Maniadakis, Vasilios Fragoulakis, Dimitrios Pectasides, George Fountzilas

    An economic analysis (based on interim data from a long-term, randomised, multi-centre, controlled, clinical trial) to evaluate chemotherapy with XELOX (capecitabine/oxaliplatin) versus FOLFOX6 (5Fluorouracil/leucovorin/oxaliplatin) as an adjuvant treatment for high risk colorectal cancer patients in Greece.As survival rate was the same in the two arms, a cost-minimisation analysis was carried out, from the perspectives of the National Health Service (NHS), Social Insurance Funds (SIF) and patients in Greece. Patient data were combined with 2008 unit prices to estimate the total cost of patient care, the patients' travelling expenditure and their productivity losses. Raw data were bootstrapped 5000 times in order to allow statistical testing.From an NHS perspective, the mean chemotherapy cost was 8762 euro with FOLFOX6 and 9713 euro with XELOX; costs of administration and hospitalisations were 5154 euro and 1050 euro, respectively. Total treatment cost with FOLFOX6 reached 17,480 euro and with XELOX 12 525 euro, a difference of 4955 euro (p < 0.001) in favour of the latter therapy. From an SIF perspective, the total cost of treatment was 16,240 euro with FOLFOX6 and 12,617 euro with XELOX, a reduction of 3623 euro (p < 0.001) with the latter therapy. Mean patient travelling cost was 184 euro with FOLFOX6 and 80 euro with XELOX, a difference of 104 euro (p < 0.001). Mean productivity loss was 100 euro with FOLFOX6 and 31 euro with XELOX, a difference of 69 euro (p < 0.001).Chemotherapy combining oral capecitabine and oxaliplatin reduces total treatment cost for the Greek National Health Service and Social Insurance Funds, mainly through a reduction in the cost of administration. From patients' perspective, it reduces travelling expenditure and productivity losses. Therefore, this combination may be a cost-effective approach for the management of colorectal cancer patients who have had surgery in Greece. This is an analysis alongside a clinical trial, and should be interpreted in this specific context in which it was undertaken.


  • Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece

    by N. Maniadakis, A. Pallis, V. Fragoulakis, P. Prezerakos, V. Georgoulias

    Introduction: An economic evaluation of the irinotecan, leucovorin, 5-fluorouracil (FOLFIRI) combination versus the irinotecan, oxaliplatin, leucovorin, 5-fluorouracil (FOLFOXIRI) regimen in patients with metastatic colorectal cancer was performed in the context of a randomised phase III study.Methods: The trial did not find any differences in efficacy and, therefore, a cost-minimisation analysis was undertaken. Treatment cost accounts for the administration of first and second line chemotherapy, for concomitant medications, for laboratory and other examinations and hospitalisations due to treatment side effects. Unit prices used reflect 2006 and are common among NHS hospitals in Greece.Results: The mean total cost of therapy in the FOLFOXIRI group (€18 344, 95% CI: €16 951–€19 776), was significantly higher than the FOLFIRI group (€12 201, 95% CI: €11 011–€13 427). Mean chemotherapy cost of the FOLFOXIRI group (€9016; 95% CI: €8338–€9669) was significantly higher than that of the FOLFIRI group (€...